Abeona Therapeutics Inc. Their mission is to deliver innovative genetic medicines that transform the lives of patients. With a vision of a world where cure is the new standard of care, Abeona is at the forefront of gene therapy research and development.

Gene therapy involves using DNA as a potential treatment for genetic diseases. Abeona aims to treat such disorders by delivering the correct copy of DNA into a patient's cells, allowing for proper cell function. Their expertise lies in developing personalized, autologous cell and gene therapies that have the potential to provide targeted and effective treatments.

Abeona's dedicated team of leaders, including Chief Executive Officer Dr. Vishwas Seshadri, Chief Medical Officer Dr. Dmitriy Grachev, Chief Technical Officer Dr.

Brian Kevany, Chief Financial Officer Joseph Vazzano, and Vice Presidents Carl Denny, Greg Gin, and Alison Hardgrove, bring extensive experience and expertise to guide the company's scientific advancements. Through their robust pipeline and clinical trials, Abeona is focused on addressing a range of serious diseases, with a particular emphasis on Recessive Dystrophic Epidermolysis Bullosa (RDEB). They are committed to collaborating with patient advocacy groups and engaging with the community to ensure the needs of patients and families are met.

Abeona also provides valuable resources for patients, families, and healthcare professionals, offering support and information about their therapies and access policies. Their dedication to innovation and their commitment to improving patients' lives make Abeona Therapeutics Inc